» Articles » PMID: 32298981

Diabetes in COVID-19: Prevalence, Pathophysiology, Prognosis and Practical Considerations

Overview
Specialty Endocrinology
Date 2020 Apr 17
PMID 32298981
Citations 378
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: High prevalence of diabetes makes it an important comorbidity in patients with COVID-19. We sought to review and analyze the data regarding the association between diabetes and COVID-19, pathophysiology of the disease in diabetes and management of patients with diabetes who develop COVID-19 infection.

Methods: PubMed database and Google Scholar were searched using the key terms 'COVID-19', 'SARS-CoV-2', 'diabetes', 'antidiabetic therapy' up to April 2, 2020. Full texts of the retrieved articles were accessed.

Results: There is evidence of increased incidence and severity of COVID-19 in patients with diabetes. COVID-19 could have effect on the pathophysiology of diabetes. Blood glucose control is important not only for patients who are infected with COVID-19, but also for those without the disease. Innovations like telemedicine are useful to treat patients with diabetes in today's times.

Citing Articles

Self-Reported Post-COVID Symptoms at 18 Months After Infection Among Adults in Southern Brazil: A Cross-Sectional Study.

de Brito F, Laranjeira C, Moroskoski M, Salci M, Rossoni S, Baccon W Healthcare (Basel). 2025; 13(3).

PMID: 39942417 PMC: 11816678. DOI: 10.3390/healthcare13030228.


Impact of COVID-19 and recovery of routine diabetic retinopathy digital screening across different regions in England: an analysis of publicly available data.

Pardhan S, Wijewickrama R, Gilbert C, Piyasena M, Sapkota R BMJ Open. 2024; 14(12):e089710.

PMID: 39732486 PMC: 11683968. DOI: 10.1136/bmjopen-2024-089710.


EpiGePT: a pretrained transformer-based language model for context-specific human epigenomics.

Gao Z, Liu Q, Zeng W, Jiang R, Wong W Genome Biol. 2024; 25(1):310.

PMID: 39696471 PMC: 11657395. DOI: 10.1186/s13059-024-03449-7.


Age-dependent effects of lockdown and post-lockdown periods on HbA1c during the COVID-19 pandemic: A 3-year longitudinal cohort study.

Sirikci V, Kirac C, Findikli H Medicine (Baltimore). 2024; 103(49):e40873.

PMID: 39654162 PMC: 11631023. DOI: 10.1097/MD.0000000000040873.


Efficient clinical decision-making process via AI-based multimodal data fusion: A COVID-19 case study.

Moris D, de Moura J, Marcos P, Miguez Rey E, Novo J, Ortega M Heliyon. 2024; 10(20):e38642.

PMID: 39640748 PMC: 11619951. DOI: 10.1016/j.heliyon.2024.e38642.


References
1.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

2.
Gorricho J, Garjon J, Alonso A, Celaya M, Saiz L, Erviti J . Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. Br J Clin Pharmacol. 2017; 83(9):2034-2044. PMC: 5555874. DOI: 10.1111/bcp.13288. View

3.
Zhang M, He J . Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019; 76(2):149-159. DOI: 10.1007/s00228-019-02786-y. View

4.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q . Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94:91-95. PMC: 7194638. DOI: 10.1016/j.ijid.2020.03.017. View

5.
Bozkurt B, Kovacs R, Harrington B . Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail. 2020; 26(5):370. PMC: 7234783. DOI: 10.1016/j.cardfail.2020.04.013. View